+Search query
-Structure paper
Title | Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses. |
---|---|
Journal, issue, pages | Nat Immunol, Vol. 23, Issue 6, Page 960-970, Year 2022 |
Publish date | Jun 2, 2022 |
Authors | Wan-Ting He / Rami Musharrafieh / Ge Song / Katharina Dueker / Longping V Tse / David R Martinez / Alexandra Schäfer / Sean Callaghan / Peter Yong / Nathan Beutler / Jonathan L Torres / Reid M Volk / Panpan Zhou / Meng Yuan / Hejun Liu / Fabio Anzanello / Tazio Capozzola / Mara Parren / Elijah Garcia / Stephen A Rawlings / Davey M Smith / Ian A Wilson / Yana Safonova / Andrew B Ward / Thomas F Rogers / Ralph S Baric / Lisa E Gralinski / Dennis R Burton / Raiees Andrabi / |
PubMed Abstract | The emergence of current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) and potential future spillovers of SARS-like coronaviruses into humans pose a major ...The emergence of current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) and potential future spillovers of SARS-like coronaviruses into humans pose a major threat to human health and the global economy. Development of broadly effective coronavirus vaccines that can mitigate these threats is needed. Here, we utilized a targeted donor selection strategy to isolate a large panel of human broadly neutralizing antibodies (bnAbs) to sarbecoviruses. Many of these bnAbs are remarkably effective in neutralizing a diversity of sarbecoviruses and against most SARS-CoV-2 VOCs, including the Omicron variant. Neutralization breadth is achieved by bnAb binding to epitopes on a relatively conserved face of the receptor-binding domain (RBD). Consistent with targeting of conserved sites, select RBD bnAbs exhibited protective efficacy against diverse SARS-like coronaviruses in a prophylaxis challenge model in vivo. These bnAbs provide new opportunities and choices for next-generation antibody prophylactic and therapeutic applications and provide a molecular basis for effective design of pan-sarbecovirus vaccines. |
External links | Nat Immunol / PubMed:35654851 / PubMed Central |
Methods | EM (single particle) |
Resolution | 25.0 Å |
Structure data | EMDB-26365: SARS-2 CoV 6P Mut7 in complex with Fab CC25.1 EMDB-26366: SARS-2 CoV 6P Mut7 in complex with Fab CC25.54 EMDB-26367: SARS-2 CoV 6P Mut7 + Fab CC25.52 EMDB-26368: SARS-2 CoV 6P Mut7 in complex with Fab CC25.56 EMDB-26369: SARS-2 CoV 6P Mut7 in complex with Fab CC25.36 EMDB-26370: SARS-2 CoV 6P Mut7 in complex with Fab CC25.3 EMDB-26371: SARS-2 CoV 6P Mut7 in complex with Fab CC25.11 EMDB-26372: SARS-2 CoV 6P Mut7 in complex with Fab CC84.5 EMDB-26373: SARS-2 CoV 6P Mut7 in complex with Fab CC84.2 EMDB-26374: SARS-2 CoV 6P Mut7 in complex with Fab CC84.10 EMDB-26375: SARS-2 CoV 6P Mut7 in complex with Fab CC84.24 |
Source |
|